CN102007139A - 用于治疗疼痛的贝洛塞平、its对映体及其类似物 - Google Patents

用于治疗疼痛的贝洛塞平、its对映体及其类似物 Download PDF

Info

Publication number
CN102007139A
CN102007139A CN2009801138213A CN200980113821A CN102007139A CN 102007139 A CN102007139 A CN 102007139A CN 2009801138213 A CN2009801138213 A CN 2009801138213A CN 200980113821 A CN200980113821 A CN 200980113821A CN 102007139 A CN102007139 A CN 102007139A
Authority
CN
China
Prior art keywords
beloxepin
pain
composition
mammal
enantiomerically pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801138213A
Other languages
English (en)
Chinese (zh)
Inventor
伯特兰·乐布尔多内克
罗兰·多勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adolor Corp
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of CN102007139A publication Critical patent/CN102007139A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
CN2009801138213A 2008-02-19 2009-02-19 用于治疗疼痛的贝洛塞平、its对映体及其类似物 Pending CN102007139A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US2991308P 2008-02-19 2008-02-19
US2991508P 2008-02-19 2008-02-19
US2991608P 2008-02-19 2008-02-19
US61/029,916 2008-02-19
US61/029,913 2008-02-19
US61/029,915 2008-02-19
US5092108P 2008-05-06 2008-05-06
US61/050,921 2008-05-06
PCT/US2009/034461 WO2009105507A2 (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain

Publications (1)

Publication Number Publication Date
CN102007139A true CN102007139A (zh) 2011-04-06

Family

ID=40986169

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801138213A Pending CN102007139A (zh) 2008-02-19 2009-02-19 用于治疗疼痛的贝洛塞平、its对映体及其类似物

Country Status (11)

Country Link
EP (1) EP2285818A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011512414A (cg-RX-API-DMAC7.html)
KR (1) KR20100137473A (cg-RX-API-DMAC7.html)
CN (1) CN102007139A (cg-RX-API-DMAC7.html)
AU (1) AU2009215541A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0908098A2 (cg-RX-API-DMAC7.html)
CA (1) CA2715192A1 (cg-RX-API-DMAC7.html)
IL (1) IL207668A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010009110A (cg-RX-API-DMAC7.html)
NZ (2) NZ594937A (cg-RX-API-DMAC7.html)
WO (1) WO2009105507A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106243096A (zh) * 2016-07-29 2016-12-21 上海璃道医药科技有限公司 三环类药物的新用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
EP4043016B1 (en) 2015-02-25 2025-10-29 The Regents of the University of California The 5ht agonist clemizole for use in treating epilepsy disorders
US10966938B2 (en) 2019-01-04 2021-04-06 Jonand4, Llc Composition and method for preventing or treating hangover symptoms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977158A (en) * 1988-08-26 1990-12-11 Akzo N.V. Dibenzoxepinon and dibenzothiepino-pyridinol or - pyrrotol derivatives with anti-depressant action

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
GB0019950D0 (en) 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
MXPA05006336A (es) * 2002-12-11 2005-08-26 Pharmacia & Up John Company Ll Combinacion para el tratamiento de adhd.
WO2005042501A1 (en) * 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
EP1828156A2 (en) * 2004-12-13 2007-09-05 Arena Pharmaceuticals, Inc. N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto
WO2006079637A1 (en) * 2005-01-27 2006-08-03 Janssen Pharmaceutica N.V. Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
CA2624096A1 (en) * 2005-09-29 2007-04-12 Wyeth Benzothiadiazolyphenylalkylamine derivatives for use in the treatment of conditions ameliorated by monoamine reuptake
CA2647835A1 (en) * 2006-03-28 2007-10-04 Neopro Labs, Llc Methods and compositions for treating conditions
GB0608655D0 (en) * 2006-05-03 2006-06-14 Merck Sharp & Dohme Therapeutic Treatment
US20070281924A1 (en) * 2006-05-31 2007-12-06 Gaeta Federico C MIF inhibitors for treating neuropathic pain and associated syndromes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977158A (en) * 1988-08-26 1990-12-11 Akzo N.V. Dibenzoxepinon and dibenzothiepino-pyridinol or - pyrrotol derivatives with anti-depressant action

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. CLAGHORN 等: "Recent developments in antidepressant agents.", 《PROGRESS IN DRUG RESEARCH》 *
MICHEL W. F. NIELEN: "Chiral separation of basic drugs using cyclodextrin-modified capillary zone electrophoresis", 《ANALYTICAL CHEMISTRY》 *
SOREN H. SINDRUP 等: "Antidepressants in the Treatment of Neuropathic Pain", 《BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106243096A (zh) * 2016-07-29 2016-12-21 上海璃道医药科技有限公司 三环类药物的新用途

Also Published As

Publication number Publication date
IL207668A0 (en) 2010-12-30
WO2009105507A2 (en) 2009-08-27
BRPI0908098A2 (pt) 2015-08-18
JP2011512414A (ja) 2011-04-21
KR20100137473A (ko) 2010-12-30
EP2285818A2 (en) 2011-02-23
NZ594937A (en) 2013-03-28
CA2715192A1 (en) 2009-08-27
AU2009215541A1 (en) 2009-08-27
MX2010009110A (es) 2010-11-30
NZ587896A (en) 2011-09-30
EP2285818A4 (en) 2011-08-17
WO2009105507A3 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
JP7223742B2 (ja) 有機化合物
BR112020019119A2 (pt) Compostos orgânicos
JP6672255B2 (ja) Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
WO2008027483A1 (en) Benzofuran derivatives as modulators of the 5-ht2a receptor
TW201216964A (en) Use of sigma ligands in opioid-induced hyperalgesia
SK2852000A3 (en) A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A H5-HT1Bì (54) ANTAGONIST OR PARTIAL AGONIST
JP6929857B2 (ja) ６，７，８，９−テトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピンドーパミンＤ３リガンド
JP2018109011A (ja) 抗不安化合物の結晶形態
CN102007139A (zh) 用于治疗疼痛的贝洛塞平、its对映体及其类似物
JP2008543782A (ja) ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト
CN101720186A (zh) (-)-e-10-oh-nt组合物及其合成与使用的方法
JP2011512414A5 (cg-RX-API-DMAC7.html)
TW201630902A (zh) 化合物、組合物及方法
US7432280B2 (en) 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake
JP2020508301A (ja) ７員アザ複素環を含有するデルタ−オピオイド受容体調節化合物、その使用方法及び製造方法
US20090233958A1 (en) (+)-beloxepin and methods for its synthesis and use
US7521462B2 (en) 4-Amino-piperidine derivatives as monoamine uptake inhibitors
US20090233957A1 (en) (-)-beloxepin and methods for its synthesis and use
SK2842000A3 (en) A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVEì (54) H5-HT1B ANTAGONIST OR PARTIAL AGONIST
US7829576B2 (en) Beloxepin and analogs for the treatment of pain
EP1856071A1 (en) Benzoxazocines and their therapeutic use
JP2008528677A (ja) Ｃｎｓの疾患および障害の処置のための四環系モノアミン再取り込み阻害薬
JP2025537554A (ja) アリールシクロアルキルアミド構造を有するイソインドリノン誘導体及びその用途
HK40040558B (zh) 可用於治疗与中枢神经系统有关的疾病或病症的n-(杂)芳基-取代的杂环衍生物
JP2025535882A (ja) Ｆｌｔ３阻害剤としての新規のｎ－ヘテロアリールベンズアミド誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110406